Collegium Pharmaceutical announced the award of 50,305 restricted stock units (RSUs) to 34 newly hired non-executive employees on June 1, 2026, as material inducement for employment. The RSUs will vest over a three-year period with one-third vesting on June 10, 2027, followed by equal annual installments, subject to continued service.

Collegium Pharmaceutical announced its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The company, which specializes in CNS and pain management medications, recently completed the acquisition of AZSTARYS and reported Q1 2026 net revenues of $193.5 million, up 9% year-over-year, with JORNAY PM revenues up 36% year-over-year.

Collegium Pharmaceutical completed its acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for approximately $650 million. The acquisition is expected to be immediately accretive and includes patent protection through 2037. Collegium raised its 2026 financial guidance, projecting total product revenues of $865-$895 million and adjusted EBITDA of $475-$500 million, with expected annual synergies exceeding $50 million.

Collegium Pharmaceutical's General Counsel David Dieter sold 6,224 shares (6.4% of his holdings) for $228,110 under a pre-planned trading arrangement. The sale is modest and non-discretionary, but the real story is Collegium's strategic pivot toward ADHD treatments, with Jornay PM growing 48% in its first full year and the company acquiring AZSTARYS for $650 million to accelerate its move away from pain management.

Collegium Pharmaceutical announced it will present two posters featuring real-world data from its pain medication portfolio at the American Academy of Pain Medicine's Annual Meeting in Salt Lake City (March 5-8, 2026). The presentations will highlight clinical insights on BELBUCA (buprenorphine buccal film) and its performance compared to other opioids, reflecting the company's focus on generating evidence for clinical practice.

Collegium Pharmaceutical announced a partnership with Paris Hilton to launch the 'Embrace Your Sparkle' campaign aimed at raising awareness about ADHD and reducing stigma. Paris Hilton shared her personal ADHD journey and her experience using JORNAY PM, an evening-dosed methylphenidate treatment designed to provide symptom support throughout the day. The campaign seeks to normalize conversations about ADHD management and encourage individuals to seek appropriate treatment.

Collegium Pharmaceutical, Inc. announced it will have two poster presentations highlighting real-world data from its ADHD treatment, Jornay PM, at the National Association of Pediatric Nurse Practitioners National Conference.

STOUGHTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference being held in New York, NY from June 5-6, 2024.

STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $35 million of the Company’s common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $115 million remaining under the program.

Throughout the last three months, 4 analysts have evaluated Collegium Pharmaceutical (NASDAQ:COLL), offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 0 0 1 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 0 0 0 Analysts have set 12-month price targets for Collegium Pharmaceutical, revealing an average target of $39.5, a high estimate of $40.00, and a low estimate of $39.00. Surpassing the previous average price target of $37.67, the current average has increased by 4.86%. Interpreting Analyst Ratings: A Closer Look The standing of Collegium Pharmaceutical among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Amsellem Piper Sandler Maintains Neutral $39.00 $39.00 Serge Belanger Needham Maintains Buy $40.00 - Les Sulewski Truist Securities Raises Buy $40.00 $37.00 David Amsellem Piper Sandler Raises Overweight $39.00 $37.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Collegium Pharmaceutical. This insight gives a snapshot of ...Full story available on Benzinga.com

The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -2.68% and 1.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?